Based on this discovery pilot study, circulating PTN and FGF-21 emerge as promising non-invasive biomarkers for improving patient stratification and supporting therapeutic evaluation in MASH, warranting validation in independent cohorts and future studies. The gene discussed is PTN; the disease is metabolic dysfunction-associated steatohepatitis.